Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10CNS 3Tumor-Agnostic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
LY-2157299 × Tumor-Agnostic × Clear all
NCT02304419 2016-10-05

A Study of Galunisertib on the Immune System in Participants With Cancer

Eli Lilly and Company

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT01722825 2014-07-01

Study of LY2157299 in Japanese Participants With Cancer

Eli Lilly and Company

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡